Clinical safety and tolerance of cefoxitin sodium: an overview

Publisher Website
Google Scholar
Abstract
Based on data from 108 studies conducted throughout the world in 2277 patients, 1924 of whom received cefoxitin (i.v. in 1749 patients and i.m. in 175), it is concluded that parenterally administered cefoxitin sodium is well tolerated by the majority of patients (more than 90%). Drug-related adverse clinical reactions occurred in about 8% of the patients. The adverse clinical experiences most frequently observed were rash (2.2% incidence) and local intolerance, including thrombophlebitis, at the site of administration (5.3% incidence). From laboratory data related to haematopoietic, renal, and hepatic functions, it appears that cefoxitin has neither unusual nor significant toxic effects on the major body systems. During therapy with cefoxitin, some patients developed a positive direct Coombs test (2.4%), eosinophilia (2.9%), or an increase in liver enzymes (ca. 3%).

This publication has 0 references indexed in Scilit: